{"id":"cyproterone-acetate","rwe":[{"pmid":"41732194","year":"2026","title":"Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.","finding":"","journal":"EClinicalMedicine","studyType":"Clinical Study"},{"pmid":"41692655","year":"2026","title":"Long-Term Effects of Gender-Affirming Hormone Therapy from Adolescence to Adulthood on Voice.","finding":"","journal":"Journal of voice : official journal of the Voice Foundation","studyType":"Clinical Study"},{"pmid":"41654592","year":"2026","title":"Changes in temperature perception in transgender persons undergoing gender-affirming hormone therapy.","finding":"","journal":"Communications medicine","studyType":"Clinical Study"},{"pmid":"41597293","year":"2025","title":"Male Rat Model of Chemical Androgen Deprivation and Estrogenization from the Perspective of Anthropometric, Histological, and Biochemical Parameters.","finding":"","journal":"Medicina (Kaunas, Lithuania)","studyType":"Clinical Study"},{"pmid":"41384221","year":"2025","title":"Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review.","finding":"","journal":"Clinical, cosmetic and investigational dermatology","studyType":"Clinical Study"}],"tags":[{"label":"cyproterone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Progesterone receptor","category":"target"},{"label":"PGR","category":"gene"},{"label":"NR3C1","category":"gene"},{"label":"AR","category":"gene"},{"label":"G03HA01","category":"atc"},{"label":"Active","category":"status"},{"label":"Androgen Antagonists","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Contraceptive Agents","category":"pharmacology"},{"label":"Contraceptive Agents, Male","category":"pharmacology"},{"label":"Hormone Antagonists","category":"pharmacology"},{"label":"Reproductive Control Agents","category":"pharmacology"}],"phase":"discontinued","safety":{"safetySignals":[{"llr":1393.687,"date":"","count":201,"signal":"Meningioma","source":"DrugCentral FAERS","actionTaken":"Reported 201 times (LLR=1394)"},{"llr":53.713,"date":"","count":14,"signal":"Hepatitis fulminant","source":"DrugCentral FAERS","actionTaken":"Reported 14 times (LLR=54)"},{"llr":47.757,"date":"","count":6,"signal":"Prosopagnosia","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=48)"},{"llr":42.818,"date":"","count":7,"signal":"Meningioma benign","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=43)"},{"llr":38.825,"date":"","count":7,"signal":"Frontotemporal dementia","source":"DrugCentral FAERS","actionTaken":"Reported 7 times (LLR=39)"}],"commonSideEffects":[{"effect":"Meningioma","drugRate":"LLR 1394","severity":"serious"},{"effect":"Hepatitis fulminant","drugRate":"LLR 54","severity":"common"},{"effect":"Prosopagnosia","drugRate":"LLR 48","severity":"common"},{"effect":"Frontotemporal dementia","drugRate":"LLR 39","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cyproviron","offLabel":[],"synonyms":["cyproterone acetate","cyproviron"],"timeline":[{"date":"1974-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"approvals":[{"date":"1974-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Cyproviron","ecosystem":[],"mechanism":{"target":"Androgen receptor, Glucocorticoid receptor, Mu-type opioid receptor","targets":[{"gene":"PGR","source":"DrugCentral","target":"Progesterone receptor","protein":"Progesterone receptor"},{"gene":"NR3C1","source":"DrugCentral","target":"Glucocorticoid receptor","protein":"Glucocorticoid receptor"},{"gene":"AR","source":"DrugCentral","target":"Androgen receptor","protein":"Androgen receptor"},{"gene":"OPRM1","source":"DrugCentral","target":"Mu-type opioid receptor","protein":"Mu-type opioid receptor"}],"modality":"Small Molecule","drugClass":"cyproterone","explanation":"Imagine your body has locks on the doors of cells that control hormones. Cyproterone acetate is a key that fits into these locks, preventing other hormones from entering and causing problems. This helps to regulate the balance of hormones in the body, particularly in conditions where there's an overproduction of androgens or estrogens.","oneSentence":"Cyproterone acetate works by binding to the progesterone receptor, thereby blocking the effects of androgens and estrogens on the body.","technicalDetail":"Cyproterone acetate exerts its effects by competitively binding to the progesterone receptor, which is a nuclear receptor that regulates gene expression in response to steroid hormones. This binding event disrupts the transcriptional activity of the progesterone receptor, leading to a decrease in the expression of androgen-responsive genes and an increase in the expression of estrogen-responsive genes."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/766","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CYPROTERONE%20ACETATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYPROTERONE ACETATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:22:37.764386","biosimilars":[],"competitors":[{"drugName":"alfentanil","drugSlug":"alfentanil","fdaApproval":"1986-12-29","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"alvimopan","drugSlug":"alvimopan","fdaApproval":"2008-05-20","patentExpiry":"Feb 12, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"anileridine","drugSlug":"anileridine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"buprenorphine","drugSlug":"buprenorphine","fdaApproval":"1981-12-29","patentExpiry":"Sep 5, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"butorphanol","drugSlug":"butorphanol","fdaApproval":"1978-08-22","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cannabidiol","drugSlug":"cannabidiol","fdaApproval":"2018-06-25","patentExpiry":"Oct 13, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cefapirin","drugSlug":"cefapirin","fdaApproval":"1974-03-12","relationship":"same-target"},{"drugName":"chlorpromazine","drugSlug":"chlorpromazine","fdaApproval":"1957-09-18","patentStatus":"Unknown","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cyproterone acetate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alfentanil","brandName":"alfentanil","genericName":"alfentanil","approvalYear":"1986","relationship":"same-target"},{"drugId":"alvimopan","brandName":"alvimopan","genericName":"alvimopan","approvalYear":"2008","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"anileridine","brandName":"anileridine","genericName":"anileridine","approvalYear":"","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"buprenorphine","brandName":"buprenorphine","genericName":"buprenorphine","approvalYear":"1981","relationship":"same-target"},{"drugId":"butorphanol","brandName":"butorphanol","genericName":"butorphanol","approvalYear":"1978","relationship":"same-target"},{"drugId":"cannabidiol","brandName":"cannabidiol","genericName":"cannabidiol","approvalYear":"2018","relationship":"same-target"},{"drugId":"cefapirin","brandName":"cefapirin","genericName":"cefapirin","approvalYear":"1974","relationship":"same-target"},{"drugId":"chlorpromazine","brandName":"chlorpromazine","genericName":"chlorpromazine","approvalYear":"1957","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01973816","phase":"PHASE3","title":"MEdical Versus SUrgical Treatments of Rectal Endometriosis","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2014-09-09","conditions":["Endometriosis"],"enrollment":78,"completionDate":"2022-10-11"},{"nctId":"NCT03043924","phase":"NA","title":"Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2017-09-26","conditions":["Polycystic Ovary Syndrome"],"enrollment":52,"completionDate":"2022-04-15"},{"nctId":"NCT06291675","phase":"","title":"Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2023-03-03","conditions":["Gender Dysphoria","Hormone Therapy Induced Morphologic Change"],"enrollment":50,"completionDate":"2033-03-03"},{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":["Gender Incongruence","Cardiovascular (CV) Risk","Cardiovascular Disease Risk Factor","Cardiovascular Disease Acute","Cardiovascular Health Status","Cardiovascular Disease (CVD)","Cardiovascular Disease Prevention"],"enrollment":500,"completionDate":"2035-12-31"},{"nctId":"NCT07145281","phase":"NA","title":"Comparing the Effects of Sublingual Estradiol Treatment Versus Oral Estradiol With Cyproterone Acetate (CPA) Treatment on The Coagulation System in Transgender Women: A Prospective, Controlled Cohort Study","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2022-11-10","conditions":["Gender Dysphoria, Adult","Blood Coagulation","Coagulation Factors","Transgender Persons, M01.777.500","Hemostasis","Transgender Women"],"enrollment":30,"completionDate":"2024-11-10"},{"nctId":"NCT05316935","phase":"PHASE2,PHASE3","title":"GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":["Endometrial Neoplasms","Atypical Endometrial Hyperplasia","Progesterone Resistance"],"enrollment":80,"completionDate":"2027-03-30"},{"nctId":"NCT07115082","phase":"PHASE1,PHASE2","title":"Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency","status":"RECRUITING","sponsor":"Yan Hongli","startDate":"2024-10-15","conditions":["Premature Ovarian Insufficiency"],"enrollment":50,"completionDate":"2026-03-30"},{"nctId":"NCT02636972","phase":"","title":"The Progression From Dysmenorrhoea to Chronic Pelvic Pain","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2014-11","conditions":["Dysmenorrhoea","Pelvic Pain","Chronic Pain"],"enrollment":56,"completionDate":"2016-01"},{"nctId":"NCT04590417","phase":"NA","title":"Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thai Red Cross AIDS Research Centre","startDate":"2022-01-24","conditions":["Drug Interaction"],"enrollment":20,"completionDate":"2025-10-01"},{"nctId":"NCT05318755","phase":"","title":"China Gender-affirming Hormone Therapy Study","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2022-04-16","conditions":["Transgender","Gender Incongruence"],"enrollment":240,"completionDate":"2028-12-31"},{"nctId":"NCT05657171","phase":"","title":"\"Effect of CPA/EE Drug on Periodontal Tissue and hsCRP Levels in PCOS Patients With Gingivitis","status":"COMPLETED","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2022-12-12","conditions":["Periodontal Diseases"],"enrollment":47,"completionDate":"2023-12-30"},{"nctId":"NCT05663892","phase":"PHASE4","title":"Drug-Drug Interaction Study in Trans Women Living With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Maple Leaf Research","startDate":"2022-11-23","conditions":["Hiv","Transgenderism"],"enrollment":45,"completionDate":"2025-01"},{"nctId":"NCT05149131","phase":"","title":"A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-17","conditions":["Metastatic Castration-sensitive Prostate Cancer"],"enrollment":960,"completionDate":"2022-08-16"},{"nctId":"NCT03151005","phase":"PHASE4","title":"The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS","status":"COMPLETED","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2017-07-01","conditions":["Polycystic Ovary Syndrome (PCOS)","Overweight","Obesity"],"enrollment":70,"completionDate":"2021-04-23"},{"nctId":"NCT04372095","phase":"","title":"Androcur® (Cyproterone Acetate) and Meningioma Development: a Genotype-environment Association Study","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-06","conditions":["Meningioma"],"enrollment":2000,"completionDate":"2025-04-19"},{"nctId":"NCT00280657","phase":"PHASE3","title":"Study on Safety and Efficacy of an Oral Contraceptive in Treating Acne Papulopustulosa","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03-10","conditions":["Acne Vulgaris"],"enrollment":1326,"completionDate":"2005-05-21"},{"nctId":"NCT04984070","phase":"NA","title":"Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01-01","conditions":["PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries","Depression, Anxiety"],"enrollment":100,"completionDate":"2024-12-31"},{"nctId":"NCT02460445","phase":"NA","title":"Phlebotomy and Polycystic Ovary Syndrome","status":"COMPLETED","sponsor":"Manuel Luque Ramírez","startDate":"2015-01","conditions":["Hyperandrogenism","Metabolic Cardiovascular Syndrome"],"enrollment":37,"completionDate":"2020-06"},{"nctId":"NCT04831151","phase":"NA","title":"The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics","status":"UNKNOWN","sponsor":"Inonu University","startDate":"2021-03-01","conditions":["Polycystic Ovary Syndrome"],"enrollment":42,"completionDate":"2023-06"},{"nctId":"NCT04964193","phase":"NA","title":"Bioequivalence Study of Cyproterone Acetate and Ethinyl Estradiol in Healthy Female Volunteers","status":"COMPLETED","sponsor":"PT Sydna Farma","startDate":"2019-03-12","conditions":["Drug Use"],"enrollment":24,"completionDate":"2019-09-26"},{"nctId":"NCT04925180","phase":"","title":"A Study to Learn About the Awareness and Knowledge That Doctors Have About the Safety and Safe Use Information for Androcur and Other Cyproterone Acetate Treatments in Europe","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-10-18","conditions":["Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea","Hypersexuality in Men","Sexual Deviations in Men","Prostate Cancer"],"enrollment":600,"completionDate":"2021-12-31"},{"nctId":"NCT05021861","phase":"","title":"Evaluation of Periodontal Status and hsCRP Levels in Females With PCOS on CPA/EE Combination Drug Regimen","status":"UNKNOWN","sponsor":"Postgraduate Institute of Dental Sciences Rohtak","startDate":"2021-11","conditions":["Periodontitis","Polycystic Ovary Syndrome","Gingivitis"],"enrollment":150,"completionDate":"2022-09-30"},{"nctId":"NCT02494297","phase":"","title":"DUS on the Prescribing Indications for CPA/EE in 5 European Countries","status":"COMPLETED","sponsor":"Center for Epidemiology and Health Research, Germany","startDate":"2015-03-06","conditions":["Hirsutism","Androgenetic Alopecia","Severe Anemia","Seborrhea","PCOS"],"enrollment":1597,"completionDate":"2016-10-31"},{"nctId":"NCT04848181","phase":"EARLY_PHASE1","title":"The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate","status":"COMPLETED","sponsor":"Benha University","startDate":"2019-07-01","conditions":["Prostate Hyperplasia"],"enrollment":60,"completionDate":"2020-07-09"},{"nctId":"NCT00003653","phase":"PHASE3","title":"Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1999-01-05","conditions":["Prostate Cancer"],"enrollment":1386,"completionDate":"2013-01-10"},{"nctId":"NCT01933204","phase":"PHASE2,PHASE3","title":"Acupuncture for Relieving Perimenopausal Symptoms","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2013-09","conditions":["Perimenopause"],"enrollment":220,"completionDate":"2015-08"},{"nctId":"NCT02689843","phase":"EARLY_PHASE1","title":"Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2018-02-01","conditions":["Polycystic Ovary Syndrome"],"enrollment":90,"completionDate":"2018-12-30"},{"nctId":"NCT04109404","phase":"","title":"Meningiomas and Treatment With CYPROTERONE ACETATE or Progestin","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2019-02-25","conditions":["Meningioma"],"enrollment":110,"completionDate":"2019-06-01"},{"nctId":"NCT02729545","phase":"PHASE2","title":"The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome","status":"COMPLETED","sponsor":"Beijing Hospital of Integrated Traditional Chinese and Western Medicine","startDate":"2016-04","conditions":["Polycystic Ovarian Syndrome"],"enrollment":60,"completionDate":"2018-05"},{"nctId":"NCT02715232","phase":"PHASE4","title":"Effects of Sex Steroids on the Serotonin System","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2017-02-06","conditions":["Gender Dysphoria"],"enrollment":92,"completionDate":"2020-12"},{"nctId":"NCT02866786","phase":"PHASE4","title":"The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS","status":"COMPLETED","sponsor":"S.C.B. Medical College and Hospital","startDate":"2016-08-15","conditions":["Polycystic Ovary Syndrome"],"enrollment":101,"completionDate":"2017-08-01"},{"nctId":"NCT03236740","phase":"PHASE4","title":"OCP vs Metformin on Ovarian Stromal Blood Flow in PCOS","status":"COMPLETED","sponsor":"S.C.B. Medical College and Hospital","startDate":"2017-08-01","conditions":["PCOS"],"enrollment":101,"completionDate":"2018-03-15"},{"nctId":"NCT02744131","phase":"NA","title":"OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women","status":"UNKNOWN","sponsor":"Kar Clinic & Hospital Pvt. Ltd.","startDate":"2016-05","conditions":["Polycystic Ovary Syndrome"],"enrollment":100,"completionDate":"2019-12"},{"nctId":"NCT03264638","phase":"PHASE2","title":"A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS","status":"UNKNOWN","sponsor":"Aijun Sun","startDate":"2016-10-01","conditions":["PCOS"],"enrollment":315,"completionDate":"2018-08-31"},{"nctId":"NCT02410031","phase":"","title":"Risk Minimisation Study for Diane-35 and Its Generics","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-26","conditions":["Acne Vulgaris"],"enrollment":759,"completionDate":"2016-03-04"},{"nctId":"NCT02349399","phase":"","title":"Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-05-01","conditions":["Acne Vulgaris"],"enrollment":26065,"completionDate":"2016-03-01"},{"nctId":"NCT02599077","phase":"PHASE2,PHASE3","title":"Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas","status":"SUSPENDED","sponsor":"Fundación Santa Fe de Bogota","startDate":"2015-11","conditions":["Endometriosis"],"enrollment":50,"completionDate":"2018-11"},{"nctId":"NCT00196339","phase":"PHASE2","title":"A Clinical Trial to Study DR-2031 for the Treatment of Hot Flashes in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Duramed Research","startDate":"2005-06","conditions":["Prostate Cancer"],"enrollment":315,"completionDate":"2008-01"},{"nctId":"NCT01011751","phase":"PHASE3","title":"Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-04","conditions":["Adenocarcinoma, Prostate"],"enrollment":311,"completionDate":"2007-12"},{"nctId":"NCT01292785","phase":"","title":"Effects of Sex Steroid Hormones on Human Brain Function, Structure and Connectivity","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2011-01","conditions":["Gender Identity Disorder"],"enrollment":80,"completionDate":"2015-04"},{"nctId":"NCT02027337","phase":"PHASE4","title":"Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants","status":"UNKNOWN","sponsor":"Tyumen State Medical Academy","startDate":"2013-12","conditions":["Polycystic Ovarian Syndrome","Hyperandrogenism","Menstrual Irregularities"],"enrollment":200,"completionDate":"2015-10"},{"nctId":"NCT01065220","phase":"PHASE4","title":"Sex Steroids and the Serotonin Transporter","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2010-02","conditions":["Transsexualism"],"enrollment":32,"completionDate":"2014-01"},{"nctId":"NCT01573377","phase":"NA","title":"Efficacy of Metformin and Diane-35 on PCOS Patients,a Randomized, Controlled, Prospective Clinical Trial","status":"COMPLETED","sponsor":"Chongqing Medical University","startDate":"2012-02","conditions":["Polycystic Ovary Syndrome","Insulin Resistance"],"enrollment":40,"completionDate":"2013-02"},{"nctId":"NCT00363285","phase":"PHASE3","title":"Cyproterone Acetate in Treating Patients With Newly Diagnosed Stage III or Stage IV Prostate Cancer","status":"UNKNOWN","sponsor":"St. Bartholomew's Hospital","startDate":"2003-01","conditions":["Prostate Cancer"],"enrollment":900,"completionDate":""},{"nctId":"NCT01819285","phase":"PHASE3","title":"Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1990-02","conditions":["Neoplasm, Prostate"],"enrollment":985,"completionDate":"2010-09"},{"nctId":"NCT00005623","phase":"PHASE3","title":"Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer","status":"COMPLETED","sponsor":"Barr Laboratories","startDate":"1999-12","conditions":["Hot Flashes","Prostate Cancer"],"enrollment":0,"completionDate":"2004-01"},{"nctId":"NCT01798875","phase":"PHASE4","title":"PCOS, Therapy and Markers of Cardiovascular Risk","status":"UNKNOWN","sponsor":"Medical University of Gdansk","startDate":"2012-04","conditions":["PCOS"],"enrollment":50,"completionDate":"2015-12"},{"nctId":"NCT00919022","phase":"","title":"Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate","status":"TERMINATED","sponsor":"Bayer","startDate":"2009-08","conditions":["Prostate Cancer"],"enrollment":194,"completionDate":"2011-08"},{"nctId":"NCT00849082","phase":"PHASE3","title":"Radiation Therapy With or Without Goserelin and Cyproterone in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1987-05","conditions":["Prostate Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00752635","phase":"PHASE4","title":"Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Johnson & Johnson Taiwan Ltd","startDate":"2004-09","conditions":["Acne Vulgaris"],"enrollment":48,"completionDate":"2005-09"},{"nctId":"NCT01103518","phase":"PHASE4","title":"Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation","status":"UNKNOWN","sponsor":"Fundação Educacional Serra dos Órgãos","startDate":"2009-12","conditions":["Amenorrhea","Dysmenorrhea","Menstruation Disturbances","Hyperandrogenism"],"enrollment":100,"completionDate":"2011-01"},{"nctId":"NCT00908674","phase":"","title":"Androcur Effects on Quality of Life","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-06","conditions":["Prostate Cancer"],"enrollment":245,"completionDate":"2010-01"},{"nctId":"NCT00955058","phase":"PHASE2,PHASE3","title":"Evaluation of Serum Prostatic Specific Antigen (PSA) After Cyproterone Compound Treatment Compared With Oral Contraceptives Pill in Hirsute Polycystic Ovary Syndrome Patients","status":"UNKNOWN","sponsor":"Shahid Beheshti University","startDate":"2007-02","conditions":["Polycystic Ovary Syndrome"],"enrollment":60,"completionDate":"2010-12"},{"nctId":"NCT00601276","phase":"PHASE3","title":"Comparison of Two Pharmacological Treatments of Pedophilia","status":"TERMINATED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2007-12","conditions":["Pedophilia"],"enrollment":48,"completionDate":"2009-06"},{"nctId":"NCT00428311","phase":"PHASE4","title":"Effects of Metformin vs Oral Contraceptives on CV Risk Markers in PCOS","status":"COMPLETED","sponsor":"Hospital Universitario Ramon y Cajal","startDate":"2004-04","conditions":["Polycystic Ovary Syndrome"],"enrollment":50,"completionDate":"2006-10"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167457","NDDF":"003475","UNII":"4KM2BN5JHF","CHEBI":"CHEBI:50743","INN_ID":"2050","RXNORM":"22054","UMLSCUI":"C0056855","ChEMBL_ID":"CHEMBL139835","KEGG_DRUG":"D01368","DRUGBANK_ID":"DB04839","PDB_CHEM_ID":" CA4","PUBCHEM_CID":"9880","SNOMEDCT_US":"126119006","IUPHAR_LIGAND_ID":"2865","SECONDARY_CAS_RN":"2098-66-0","MESH_DESCRIPTOR_UI":"D017373"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2719,"therapeuticAreas":["Pain"],"atcClassification":{"source":"DrugCentral","atcCode":"G03HA01","allCodes":["G03HA01","G03HB01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb","pmid":"41732194","title":"Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.","journal":"EClinicalMedicine"},{"date":"2026 Feb 14","pmid":"41692655","title":"Long-Term Effects of Gender-Affirming Hormone Therapy from Adolescence to Adulthood on Voice.","journal":"Journal of voice : official journal of the Voice Foundation"},{"date":"2026 Feb 7","pmid":"41654592","title":"Changes in temperature perception in transgender persons undergoing gender-affirming hormone therapy.","journal":"Communications medicine"},{"date":"2025 Dec 19","pmid":"41597293","title":"Male Rat Model of Chemical Androgen Deprivation and Estrogenization from the Perspective of Anthropometric, Histological, and Biochemical Parameters.","journal":"Medicina (Kaunas, Lithuania)"},{"date":"2025","pmid":"41384221","title":"Efficacy and Safety of Hormonal Therapies for Acne: A Narrative Review.","journal":"Clinical, cosmetic and investigational dermatology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"discontinued","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyproterone acetate is a synthetic steroid and a member of the cyproterone class of drugs. It primarily targets the progesterone receptor, which plays a crucial role in the regulation of the menstrual cycle and fertility. As a small molecule, cyproterone acetate is used to treat conditions such as acne, hirsutism, and precocious puberty in children. However, its commercial status and FDA approval are unknown. Further research is needed to determine its efficacy and safety in various clinical settings.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1974-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}